Could be the problem with GILD. Not enough M&A. You got a point.
Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. The company's shares, which rose 2.3 percent to close at $113.07 on Nasdaq, were up another 2.3 percent at $115.82 after hours.
Fishing for it. Said it was revised but can't find numbers yet.
yep. FY 2015: $15.50 to $15.95 as opposed to estimates of $16.63 and cut revenue outlook to 6% to 8% vs 13%. Not good,
Volume is picking up. Smart money is adding here.